It was a great pleasure to meet with Jeffrey Strich (National Institutes of Health Clinical Center, Bethesda, MD, USA) to discuss the findings from a recent phase 2 study investigating fostamatinib for the treatment of hospitalized adults with COVID-19.
Useful Resources:
Published data available here: Fostamatinib for the treatment of hospitalized adults with COVID-19 A randomized trial
Questions:
- What is the rationale for adding fostamatinib to standard of care in hospitalised COVID-19 patients? (0:15)
- Could you tell us a little about the aims and design of your recent Phase II study? (3:30)
- What were the efficacy and safety findings of the study? (5:04)
- What were the conclusions of the investigators? (7:17)
- What questions remain unanswered and what further studies are planned? (8:21)
Disclosures: Jeffrey Strich has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
